Moreover, emerging data suggest these agents promote favorable cardiac remodeling even in conditions like transthyretin amyloid cardiomyopathy, where SGLT2i use alongside tafamidis was associated with improved cardiac function and structure in real-world analyses [27]. This evidence concerns the gene TTR and cardiac amyloidosis.